Azithromycin Inhibits the Replication of Zika Virus

Bosseboeuf, Eve; Aubry, Maïté; Nhan, Tu-Xuan; Jj, De Pina; Rolain, Jean Marc; Raoult, Didier; Musso, Didier

doi:10.4172/1948-5964.1000173

Cited by 115 publications

(113 citation statements)

References 45 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…Repositioning of drugs for use as antiviral treatments is a critical need [1]. It is commonly very badly perceived by virologists, as we experienced when reporting the effectiveness of azithromycin for Zika virus [2]. A response has come from China to the respiratory disease caused by the new coronavirus (SARS-CoV-2) that emerged in December 2019 in this country.…”

mentioning

confidence: 99%

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Colson

Rolain

Lagier

et al. 2020

International Journal of Antimicrobial Agents

Self Cite

863

738

View full text Add to dashboard Cite

mentioning

confidence: 99%

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Colson

Rolain

Lagier

et al. 2020

International Journal of Antimicrobial Agents

Self Cite

863

738

View full text Add to dashboard Cite

“…Azithromycin has been displayed an antiviral property against Zika and Ebola virus in vitro (Bosseboeuf et al, 2018;Madrid et al, 2015;Retallack et al, 2016). It can prevent severe respiratory tract infection in the case of viral infected patients (Bacharier et al, 2015).…”

Section: Trial Test Of the Fda-approved Drugs For Covid-19 Patientsmentioning

confidence: 99%

Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment

Boopathi

Poma

Kolandaivel

2020

Journal of Biomolecular Structure and Dynamics

471

491

View full text Add to dashboard Cite

In the past two decades, the world has faced several infectious disease outbreaks. Ebola, Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms of economic disruption, the strain on local and global public health. Most recently, the global outbreak of novel coronavirus 2019 (SARS-CoV-2) that causes COVID-19 is a newly discovered virus from the coronavirus family in Wuhan city, China, known to be a great threat to the public health systems. As of 15 April 2020, The Johns Hopkins University estimated that the COVID-19 affected more than two million people, resulting in a death toll above 130,000 around the world. Infected people in Europe and America correspond about 40% and 30% of the total reported cases respectively. At this moment only few Asian countries have controlled the disease, but a second wave of new infections is expected. Predicting inhibitor and target to the COVID-19 is an urgent need to protect human from the disease. Therefore, a protocol to identify anti-COVID-19 candidate based on computer-aided drug design is urgently needed. Thousands of compounds including approved drugs and drugs in the clinical trial are available in the literature. In practice, experimental techniques can measure the time and space average properties but they cannot be captured the structural variation of the COVID-19 during the interaction of inhibitor. Computer simulation is particularly suitable to complement experiments to elucidate conformational changes at the molecular level which are related to inhibition process of the COVID-19. Therefore, computational simulation is essential tool to elucidate the phenomenon. The structure-based virtual screening computational approach will be used to filter the best drugs from the literature, the investigate the structural variation of COVID-19 with the interaction of the best inhibitor is a fundamental step to design new drugs and vaccines which can combat the coronavirus. This mini-review will address novel coronavirus structure, mechanism of action, and trial test of antiviral drugs in the lab and patients with COVID-19.

show abstract

“…In vitro studies have shown that azithromycin is active against Zika and Ebola viruses, [18][19][20] and is able to prevent severe respiratory tract infections when administrated to patients suffering viral infection [12] However, the efficacy of azithromycin in combination with hydroxychloroquine in the treatment of COVID-19 patients has not been confirmed yet [21,22], and more studies are needed to further investigate its clinical effects. In light of the current shift of dental services towards the provision of emergency treatment only, and the possible increase in antibiotic prescriptions for severe orofacial infections, the use of azithromycin in dentistry should be monitored, especially that its use in dental practice as a favorable antibiotic is reported in countries with a high toll of COVID-19 infections.…”

Section: Azithromycinmentioning

confidence: 99%

COVID-19: Present and Future Challenges for Dental Practice

Dar‐Odeh

Babkair

Abu‐Hammad

et al. 2020

IJERPH

145

View full text Add to dashboard Cite

COVID-19 was declared a pandemic by the World Health Organization, with a high fatality rate that may reach 8%. The disease is caused by SARS-CoV-2 which is one of the coronaviruses. Realizing the severity of outcomes associated with this disease and its high rate of transmission, dentists were instructed by regulatory authorities, such as the American Dental Association, to stop providing treatment to dental patients except those who have emergency complaints. This was mainly for protection of dental healthcare personnel, their families, contacts, and their patients from the transmission of virus, and also to preserve the much-needed supplies of personal protective equipment (PPE). Dentists at all times should competently follow cross-infection control protocols, but particularly during this critical time, they should do their best to decide on the emergency cases that are indicated for dental treatment. Dentists should also be updated on how this pandemic is related to their profession in order to be well oriented and prepared. This overview will address several issues concerned with the COVID-19 pandemic that directly relate to dental practice in terms of prevention, treatment, and orofacial clinical manifestations.

show abstract

Azithromycin Inhibits the Replication of Zika Virus

Cited by 115 publications

References 45 publications

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment

COVID-19: Present and Future Challenges for Dental Practice

Contact Info

Product

Resources

About